article thumbnail

AskBio Receives FDA Fast Track Designation for AB-1002 Investigational Gene Therapy Program in Congestive Heart Failure

DAIC

Inhibiting the function of this protein, which is linked to congestive heart failure (CHF), could potentially lead to a therapeutic effect on the heart.1,2 Inhibiting the function of this protein, which is linked to congestive heart failure (CHF), could potentially lead to a therapeutic effect on the heart.1,2

article thumbnail

AskBio Announces Initiation of Phase 2 GenePHIT Trial in Congestive Heart Failure (CHF)

DAIC

(AskBio), a gene therapy company wholly owned and independently operated as a subsidiary of Bayer AG , announced that it is initiating GenePHIT (Gene PHosphatase Inhibition Therapy), a Phase 2 trial of AB-1002 (also known as NAN-101 ) for the treatment of congestive heart failure (CHF). Heart failure. Published 2022.

article thumbnail

Machine Learning Informs a New Tool to Guide Treatment for Acute Decompensated Heart Failure

DAIC

Matthew Segar co-authored a study in JACC Heart Failure led by his research and residency mentor, University of Texas Southwestern Medical Center's Dr. Ambarish Pandey , that utilized a machine learning-based-approach to identify, understand, and predict diuretic responsiveness in patients with acute decompensated heart failure (ADHF).

article thumbnail

Recognizing Cirrhosis as a Public Health Burden: Cost of Care Tops COPD, Heart Failure

HCPLive

The analysis of UnitedHealth Group claims data found the per-patient cost of cirrhosis care exceeded that of HF and COPD by 21.7% and 55.0%, respectively.

article thumbnail

Global study highlights the life-saving impact of guideline-directed medical therapy in heart failure patients

Medical Xpress - Cardiology

Heart failure is a rapidly growing public health issue that can be difficult to manage on a global scale. But there are tools that exist that can improve outcomes, such as guideline-directed medical therapy (GDMT).

article thumbnail

HeartSciences Announces Allowance of U.S Patent for AI-ECG Assessment of Left Ventricular and Right Ventricular Heart Dysfunction

DAIC

Heart failure (HF) is a growing worldwide public health issue affecting 64 million people annually 1 and is associated with high mortality, lower quality of life and reduced physical capacity while placing substantial costs on the healthcare system.

article thumbnail

Top Cardiology Conferences in 2025

Cardiology Update

This event encompasses various facets, including public health, primary care, secondary prevention, rehabilitation, sports cardiology, and exercise. This includes the establishment of networks dedicated to its management, education, and research, as well as Late-Breaking Science.